Science

Heidi Ko: Our latest mini-review on HER2 as a tumor-agnostic biomarker

Heidi Ko/LinkedIn

Mar 4, 2025, 11:22

Heidi Ko: Our latest mini-review on HER2 as a tumor-agnostic biomarker

Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared an article on LinkedIn:

“Excited to share that our latest mini-review on HER2 as a tumor-agnostic biomarker is now published in Frontiers in Oncology!

We delved into the evolving role of HER2 overexpression in various solid tumors and discussed how advancements in Antibody Drug Conjugates, particularly T-DXd, are transforming treatment strategies in solid malignancies.

We also addressed the challenges in HER2 testing across pan solid tumors and the potential of NGS and AI algorithms to enhance diagnostic accuracy.

Check out the full article here.”

From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates.

Authors: Heidi C Ko, et al.

More posts featuring Heidi Ko.

antibody biomarker cancer fight against cancer Frontiers in Oncology Global fight against cancer Heidi Ko HER2 Labcorp Drug Development OncoDaily Oncology T-Dxd

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term